Gouty Arthritis (Gout) Pipeline Insights, 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Gouty Arthritis (Gout) - Pipeline Insights, 2017" drug pipelines to their offering.

Gouty Arthritis (Gout) - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Gouty Arthritis (Gout). This report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration.

Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. This report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Gouty Arthritis (Gout).

This report also assesses the Gouty Arthritis (Gout) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Scope:

  • The report provides competitive pipeline landscape of Gouty Arthritis (Gout)
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Gouty Arthritis (Gout) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Gouty Arthritis (Gout) and also provide company profiling
  • The report also gives the information of dormant and discontinued pipeline projects
  • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Key Topics Covered:

  1. Gouty Arthritis (Gout) Overview
  2. Gouty Arthritis (Gout) Pipeline Therapeutics
  3. Gouty Arthritis (Gout) Therapeutics under Development by Companies
  4. Gouty Arthritis (Gout) Filed and Phase III Products
  5. Gouty Arthritis (Gout) Phase II Products
  6. Gouty Arthritis (Gout) Phase I and IND Filed Products
  7. Gouty Arthritis (Gout) Discovery and Pre-Clinical Stage Products
  8. Drug Candidate Profiles
  9. Gouty Arthritis (Gout) - Therapeutics Assessment
  10. Companies Involved in Therapeutics Development for Gouty Arthritis (Gout)
  11. Appendix

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/nj5h93/gouty_arthritis

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Musculoskeletal Disorders Drugs